Navigation Links
Novel bee venom derivative forms a nanoparticle 'smart bomb' to target cancer cells
Date:8/2/2010

The next time you are stung by a bee, here's some consolation: a toxic protein in bee venom, when altered, significantly improves the effectiveness liposome-encapsulated drugs or dyes, such as those already used to treat or diagnose cancer. This research, described in the August 2010 print issue of the FASEB Journal (http://www.fasebj.org), shows how modified melittin may revolutionize treatments for cancer and perhaps other conditions, such as arthritis, cardiovascular disease, and serious infections.

"This type of transporter agent may help in the design and use of more personalized treatment regimens that can be selectively targeted to tumors and other diseases," said Samuel A. Wickline, Ph.D., a researcher involved in the work from the Consortium for Translational Research in Advanced Imaging and Nanomedicine (C-TRAIN) at the Washington University School of Medicine in St. Louis, Missouri.

To make this discovery, Wickline and colleagues designed and tested variations of the melittin protein to derive a stable compound that could be inserted into liposomal nanoparticles and into living cells without changing or harming them. They then tested the ability of this protein, or "transporter agent," to attach to different therapeutic compounds and enhance drug therapy without causing harmful side effects. In addition, their results suggest that the base compound which is used to create the transporter agent may improve tumor therapy as well.

"Our journal is abuzz in a hive of bee-related discoveries. Just last month, we published research showing for the first time how honey kills bacteria. This month, the Wickline study shows how bee venom peptides can form "smart bombs" that deliver liposomal nanoparticles directly to their target, without collateral damage," said Gerald Weissmann, M.D., Editor-in-Chief of the FASEB Journal.


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Page: 1

Related biology news :

1. Scientists identify novel inhibitor of human microRNA
2. Conaway Lab identifies novel mechanism for regulation of gene expression
3. LIAI launches new division to look at novel approaches to heart disease and inflammation
4. Childrens National researchers develop novel anti-tumor vaccine
5. Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer
6. Novel publishing approach puts textbook in more hands
7. GEN reports on novel tools for deciphering biological networks
8. UT Southwestern researcher awarded Gates Foundation grant for novel vaccine development
9. 3-substituted indolones as novel therapeutic compounds for neurodegenerative conditions
10. Corn researchers discover novel gene shut-off mechanisms
11. A novel target for therapeutics against Staph infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
(Date:11/14/2016)... Calif. , Nov. 14, 2016 /PRNewswire/ ... biometric identification market, Frost & Sullivan recognizes ... & Sullivan Award for Visionary Innovation Leadership. ... in the biometric identification market by pioneering ... verification solution for instant, seamless, and non-invasive ...
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... ... 2016 , ... In anticipation of AxioMed’s exclusive cleanroom manufacturing ... President, Jake Lubinski will be traveling to Germany on December 6th. Mr. Lubinski ... Karlsruhe to discuss the benefits of a viscoelastic total disc replacement. , AxioMed ...
(Date:12/5/2016)... Dec. 5, 2016  Eisai Inc. announced today ... study of rufinamide, which were presented at the ... (AES) held from December 2-6 in ... safety, tolerability and cognitive data showed that patients ... safety and tolerability profiles, cognitive development and behavior, ...
(Date:12/4/2016)... 2016  In five studies being presented today during ... and Exposition in San Diego , ... the delivery of life-saving treatments to patients with a ... to carry therapies directly to the sites in the ... a substantial advantage over traditional, systemic methods. The studies ...
(Date:12/2/2016)... THOUSAND OAKS, Calif. , Dec. 2, 2016 ... AGN ) today announced the submission of a ... for ABP 215, a biosimilar candidate to Avastin ® ... biosimilar application submitted to the EMA. "The ... milestone as Amgen seeks to expand our oncology portfolio," said ...
Breaking Biology Technology: